Company patents

MILTENYI BIOTEC B.V. & CO. KG

Miltenyi Biotec B.V. & Co KG's patent strategy reveals a strong, sustained focus on core areas like Material & Chemical Analysis (32.3% of portfolio) and Pharmaceutical Preparations (28.0%), with a surprising surge in Pharmaceutical Preparations patents in 2024, growing by 140.0% YoY, indicating a significant, albeit potentially short-lived, emerging focus in that year. While most categories show a decline in filings so far in 2026, the consistent high share of these two categories suggests a foundational commitment to both analytical tools and therapeutic development.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

93 US filings (since 2023) · 11 categories · 18 themes

Advanced Cell & Gene Therapies

Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.

Pharmaceutical PreparationsPeptides & Proteins
Who else files here? →
36since 2023
-21.4%YoY
Advanced Biomarker Detection Assays

Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.

Material & Chemical Analysis
Who else files here? →
29since 2023
+28.6%YoY
Cellular Immunotherapy

Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.

Therapeutic Activity (Pharma)
Who else files here? →
24since 2023
-45.5%YoY
Antibody Engineering & Therapeutics

Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.

Pharmaceutical PreparationsPeptides & ProteinsMaterial & Chemical AnalysisTherapeutic Activity (Pharma)
Who else files here? →
23since 2023
-40.0%YoY
Nucleic Acid Capture & Prep

Methods and reagents designed to improve the specificity, efficiency, or yield of nucleic acid capture, ligation, amplification, or library preparation steps, particularly for sequencing applications or quantitative analysis.

Genetic & Microbiological Assays
Who else files here? →
22since 2023
0.0%YoY
Cell Therapy & Bioproduction Processes

Methods and apparatus specifically tailored for the expansion, differentiation, or genetic modification of cells for therapeutic applications (e.g., CAR T cells, progenitor cells) or for the production of specific biological products (e.g., cultured fat, RNA).

Bioreactors / Cell Culture Apparatus
Who else files here? →
13since 2023
-42.9%YoY
Nucleic Acid-Based Therapies

Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.

Pharmaceutical PreparationsTherapeutic Activity (Pharma)
Who else files here? →
11since 2023
+100.0%YoY
CRISPR-based Nucleic Acid Detection

Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.

Genetic & Microbiological Assays
Who else files here? →
11since 2023
-33.3%YoY
Integrated Molecular Diagnostic Systems

Self-contained or modular devices designed to automate and integrate multiple steps of molecular diagnostic assays, from sample preparation to result interpretation, often for point-of-care or high-throughput applications.

Genetic & Microbiological AssaysLaboratory Apparatus
Who else files here? →
8since 2023
+100.0%YoY
Immunomodulatory Protein Design

Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.

Peptides & Proteins
Who else files here? →
7since 2023
+100.0%YoY
In Vitro Disease Modeling & Cell Engineering

Development and use of engineered biological systems, such as organ-on-a-chip devices, dynamic hydrogels, or genetically modified cells, to mimic physiological conditions, study disease mechanisms, screen compounds, or develop cell-based therapies.

Material & Chemical Analysis
Who else files here? →
5since 2023
0.0%YoY
Immune Checkpoint Modulation

Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.

Therapeutic Activity (Pharma)
Who else files here? →
4since 2023
new
Advanced Optical Imaging & Lens Design

Development of sophisticated optical lens assemblies and computational methods to achieve high-resolution, precise, or specialized imaging, often for medical or scientific applications.

Optical Elements & Systems
Who else files here? →
4since 2023
0.0%YoY
Bioprocess Development for Proteins

Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.

Peptides & Proteins
Who else files here? →
3since 2023
0.0%YoY
Microfluidic Lab-on-Chip Devices

Miniaturized devices that manipulate small volumes of fluids (nanoliters to picoliters) through microchannels to perform laboratory functions like mixing, separation, reaction, and detection on a single chip.

Laboratory Apparatus
Who else files here? →
2since 2023
new
Molecular Biomarkers for Disease

Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.

Genetic & Microbiological Assays
Who else files here? →
2since 2023
n/a
Rapid Isothermal Amplification

Methods and kits for amplifying nucleic acids at a constant temperature, enabling faster results and point-of-care applications, often used for pathogen or contamination detection.

Genetic & Microbiological Assays
Who else files here? →
1since 2023
n/a
Automated Bioreactor Control

Systems and methods for automated monitoring and dynamic adjustment of environmental parameters (e.g., pH, temperature, oxygen, nutrients) and fluid handling within bioreactors to optimize cell/tissue growth or product synthesis.

Bioreactors / Cell Culture Apparatus
Who else files here? →
1since 2023
n/a

Patents

Showing 1-10 of 133

Page 1 of 14
US 20260049301 A1APPLICATION
C12N15/10

Barcoding of Nucleic Acids from Single Cells

Filed:2023-08-02Pub:2026-02-19
Applicant:Miltenyi Biotec B.V. & Co. KG

The invention provides a method which allows the separation of different workflow steps for barcoding of target nucleic acids and therefore providing optimal reaction conditions for each workflow step, especially for template switching reactions. Moreover this method provides the opportunity to perform the reactions such as barcoding reactions of two different nucleic acid molecules from one cell such as RNA and genomic DNA molecules in a single step. The method comprises the steps: (a) Providing a plurality of cells comprising target RNA molecules and at least one solid support comprising capture oligonucleotides for said target RNA molecules and barcode oligonucleotides; (b) Partitioning said plurality of cells and said solid supports such that each cell is included into a separate partition and each partition comprises a solid support; (c) Lysing said cell, thereby obtaining a mixture of target and non, target RNA molecules; (d) Hybridizing said target RNA molecules to the capture oligonucleotides for said target RNA molecules, thereby obtaining target RNA molecules attached to said solid support (e) Disrupting the partitions and separating the non-target RNA molecules from the target RNA molecules attached to said solid support (f) Generating double stranded nucleic acids from the target RNA molecules by nucleic acid synthesis, wherein the capture oligonucleotides serve as primer and the target RNA molecules serve as templates (g) Attaching the barcode oligonucleotides to the double stranded nucleic acids from target RNA molecules, thereby generating barcoded nucleic acids from target RNA molecules; Characterized in that in step a) said plurality of cells additionally comprise target genomic DNA molecules and said at least one solid support additionally comprise capture oligonucleotides for target genomic DNA molecules and in that the capture oligonucleotides for target RNA and target genomic DNA molecules are different.